Barb, Diana

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 2,667

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,021

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Lomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 354

Successful aging: Advancing the science of physical independence in older adults

Anton, S. D., Woods, A. J., Ashizawa, T., Barb, D., Buford, T. W., Carter, C. S., Clark, D. J., Cohen, R. A., Corbett, D. B., Cruz-Almeida, Y., et al. (2015) · Ageing Research Reviews

Balance, Gait, and Falls PreventionAging and Gerontology Research

Cited by 292

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 204

Pharmacological management of nonalcoholic fatty liver disease

Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 114

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 101

Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD

Kalavalapalli, S., Leiva, E. G., Lomonaco, R., Chi, X., Shrestha, S., Dillard, R., Budd, J., Romero, J. P., Li, C., Bril, F., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis

Bril, F., Barb, D., Lomonaco, R., Lai, J., & Cusi, K. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 55

Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes

Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K. (2019) · Diabetes Care

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 52